PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 21, 2023New England Journal of Medicine284 citationsOpen Access

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

JHJessica C. HasselSPSophie Piperno‐NeumannPRPiotr Rutkowski

Key Points

Key points are not available for this paper at this time.

Abstract

This 3-year analysis supported a continued long-term benefit of tebentafusp for overall survival among adult HLA-A*02:01-positive patients with previously untreated metastatic uveal melanoma. (Funded by Immunocore; IMCgp100-202 ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hassel et al. (2023) studied this question.

synapsesocial.com/papers/69d96fcf5e5bcb4e3b8366dehttps://doi.org/10.1056/nejmoa2304753
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma2021 · 909 citations
  2. 2Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma2022 · 70 citations
  3. 3Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma2022 · 85 citations
  4. 4Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial2022 · 161 citations
  5. 5Uveal melanoma2020 · 859 citations